Sean Dulloo, MRCP (MD)

Dr. Sean Dulloo is a Consultant and Medical Oncologist at the University Hospitals of Leicester NHS Trust UK.  Dr. Dulloo received his medical training through the National University Health System including residency at the University of Singapore. He also earned a Master’s of Science in Health Economics from the London School of Economics and Political Science. Dr. Dulloo is a Research Investigator for the RS Oncology MITOPE Trial of RSO-021 in pleural mesothelioma and has presented key findings from ongoing trials. He has also published independent research on the need for precision therapy for mesothelioma patients who are lacking treatment options.

Dean Fennell, MRCP, FRCP (MD/PhD)

Dr. Dean Fennell is a Professor of Thoracic Oncology and the Director of the Mesothelioma Research Program at the University of Leicester, UK. Professor Fennell is a dedicated consultant medical oncologist leading a clinical trial-based practice in the NHS focusing on early and late phase trials for mesothelioma. As a Key Opinion Leader, Dr. Fennell has held leadership roles in several organizations including the International Mesothelioma Interest Group (IMIG), National Cancer Research Institute (NCRI) Mesothelioma Subgroup, the Board of European Organization for the Treatment Research of Cancer (EORTC) and the International Association for the Study of Lung Cancer (IASLC) mesothelioma Taskforce. He has also co-authored European and British Mesothelioma Treatment Guidelines.

James Spicer, MRCP, FRCP (MD/PhD)

Dr. James Spicer is a Professor of Experimental Cancer Medicine at the King’s College in London funded by Cancer Research UK and National Institute for Health Research. He also serves as an Honorary Consultant in Medical Oncology at Guy’s and St. Thomas’ Hospitals NHS Foundation Trust UK. Professor Spicer trained at major London teaching hospitals, has a Ph.D. in cancer biology from the Institute of Cancer Research in London, and a degree in biochemistry from the University of Oxford. Professor Spicer’s interests include the development of new cancer drugs and the care of patients with thoracic malignancies, including lung cancer and mesothelioma. His research interests include early phase trials and novel immunotherapies.